Gastroenterologia Japonica

, Volume 18, Issue 2, pp 128–136 | Cite as

Usefulness of antithrombin III and α2-plasmin inhibitor in early differentiation of fulminant hepatitis and severe form of acute hepatitis

  • Shunichi Sato
  • Akihiko Murakami
  • Toshimi Yoshida
  • Toshifumi Kashiwabara
  • Kazuyuki Suzuki
  • Isamu Kaito
Original Article


To evaluate the usefulness of antithrombin III (AT III) and α2 -plasmin inhibitor (α2PI) in early differential diagnosis of fulminant hepatitis from the severe form of acute hepatitis, the activities of AT III and α2PI were measured in plasma of 15 patients with fulminant hepatitis and 6 patients with severe form of acute hepatitis. The activities of prothrombin time (PT), hepaplastintest (HPT) and thrombotest (TT) were also evaluated. The mean values and the standard errors (SE) for PT, HPT and TT were 21.1 ±2.6%, 14.0 ±1.6% and 10.3 ±1.7%, respectively, in the early stage of fulminant hepatitis and 25.3 ±2.4%, 21.6 ±4.6% and 15.8 ±3.6%, respectively, in the severe form of acute hepatitis. No significant difference in the tests between these two diseases was noted. On the other hand, the mean values ±SE for AT III and α2PI were 13.7 ±4.6% and 25.6 ±8.6% in fulminant hepatitis and 70.2 ±28.5% and 98.7 ±9.7% in the severe form of acute hepatitis. A significant difference between the two diseases was observed. From the above, it is concluded that measuring AT III and α2Pl along with PT, HPT and TT is useful for early diagnosis of fulminant hepatitis.

Key words

fulminant hepatitis severe form of acute hepatitis AT HI α2PI 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Hillenbrand P, et al: Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut 15: 83, 1974PubMedCrossRefGoogle Scholar
  2. 2).
    Owren PA: Blood coagulation in liver diseases. Blood & Vessel 8: 1, 1977Google Scholar
  3. 3).
    Yamashina A: Experimental and clinical studies on blood coagulation in liver diseases. Acta Hepatologica Jpn l7:425, 1976 (Jpn)Google Scholar
  4. 4).
    Quick AJ: Prothrombin in hemophilia and in obstructive jaundice. J Biol Chem 109: 73, 1935Google Scholar
  5. 5).
    Owren PA, et al: Normotest. Farmakoterapi 25: 14, 1969Google Scholar
  6. 6).
    Owren PA: Thrombotest. A new method for controlling anticoagulant therapy. Lancet 2: 754, 1959PubMedCrossRefGoogle Scholar
  7. 7).
    Clauss A: Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haem 17: 237, 1957Google Scholar
  8. 8).
    Astrup T, et al: Fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 40: 346, 1952PubMedCrossRefGoogle Scholar
  9. 9).
    Fujimaki M, et al: Immunological determination of FDP. Clinical Immunology 6: 557, 1974 (Jpn)Google Scholar
  10. 10).
    Ødegord OR, et al: Heparin cofactor activity measured with an amidolytic method. Thrombo Res 6: 287, 1975CrossRefGoogle Scholar
  11. 11).
    Naito K, et al: Assay of α2plasmin inhibitor activity by means of a plasma specific tripeptide substrate. Thrombo Res 12: 1147, 1978CrossRefGoogle Scholar
  12. 12).
    Iwabuchi S, et al: Clinical significance of antithrombin III activity in liver disease. Blood & Vessel 12: 412, 1981 (Jpn)Google Scholar
  13. 13).
    Aoki N, et al: The α2plasmin inhibitor levels in liver diseases. Clini Chim Acta 84: 99, 1978CrossRefGoogle Scholar
  14. 14).
    Boyadjian H: Changes in antithrombin III activity in the various clinical forms of viral hepatitis. Folia Medica 23: 11, 1981PubMedGoogle Scholar
  15. 15).
    Cucuianu MP, et al: Increased plasma antithrombin III level in hyperlipidemic subjects. Clin Chim Acta 110: 147, 1981PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Gastroenterology 1983

Authors and Affiliations

  • Shunichi Sato
    • 1
  • Akihiko Murakami
    • 1
  • Toshimi Yoshida
    • 1
  • Toshifumi Kashiwabara
    • 1
  • Kazuyuki Suzuki
    • 1
  • Isamu Kaito
    • 1
  1. 1.The First Department of Internal MedicineIwate Medical UniversityMoriokaJapan

Personalised recommendations